This is the old version of SRDR. The next, SRDRplus is available! Registration of your SRDRPlus account is free and approval is automatic. Click Here to register an SRDRPlus account.

  • Home
  • Published Projects
  • Registries
Advanced Search

Study Preview



Study Title and Description

Prospective randomized trial comparing short-term antibiotic therapy versus standard therapy for acute uncomplicated sigmoid diverticulitis.



Key Questions Addressed
2 KEY QUESTION 2 KQ 2: What are the benefits and harms of various treatment options for the treatment of acute diverticulitis? KQ 2a. For patients with acute uncomplicated diverticulitis, what are the effectiveness and harms of hospitalization versus outpatient management of the acute episode? • Do the effects and harms vary by patient characteristics, presentation or course of illness, or other factors? KQ 2b. For patients with acute uncomplicated or complicated diverticulitis, what are the effects, comparative effects, and harms of antibiotics? • Do the effects and harms vary between patients with complicated or uncomplicated diverticulitis? • Do the (comparative) effects and harms vary by route of administration of antibiotics, type of antibiotic, and duration of course of antibiotics? • Do the (comparative) effects and harms vary by patient characteristics, presentation or course of illness, or other factors? KQ 2c. For patients with acute complicated diverticulitis, what are the effects and harms of interventional radiology procedures compared with conservative management? • Do the effects and harms vary by patient characteristics, presentation or course of illness, or other factors?
  • Comments Comments (
    0
    ) |
  • Post/View

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Prospective randomized trial comparing short-term antibiotic therapy versus standard therapy for acute uncomplicated sigmoid diverticulitis.
Author Schug-Pass C., Geers P., Hügel O., Lippert H., Köckerling F.
Country Department of Surgery, Center for Minimally Invasive Surgery, Vivantes Hospital Spandau, Neue Bergstrasse 6, 13585 Berlin, Germany. christine.schug-pass@vivantes.de
Year 2010
Numbers Pubmed ID: 20140619

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Extraction Form for KQs 2 and 4
Arms
Number Title Description Comments
1 Antibiotic: Ertapenem 4 days
  • Comments Comments (
    0
    ) |
2 Antibiotic: Ertapenem 7 days
  • Comments Comments (
    0
    ) |

Design Details
Question... Follow Up Answer Follow-up Answer
Specific KQ KQ 2b: Antibiotics (acute)
  • Comments Comments (
    0
    ) |
KQ 2b: Antibiotics (acute)
  • Comments Comments (
    0
    ) |
Study Design RCT
  • Comments Comments (
    0
    ) |
RCT
  • Comments Comments (
    0
    ) |
Country Germany
  • Comments Comments (
    0
    ) |
Germany
  • Comments Comments (
    0
    ) |
Funder Industry (fully or in part)
  • Comments Comments (
    0
    ) |
Study name
  • Comments Comments (
    0
    ) |
Associated articles
  • Comments Comments (
    0
    ) |
ClinicalTrials.gov identifier NCT00097734
  • Comments Comments (
    0
    ) |
Start and end years of the Study 2004
  • Comments Comments (
    0
    ) |
2008
  • Comments Comments (
    0
    ) |
Inclusion criteria Age 18-75 yo. Has at least 2 of following symptoms: fever, abdominal resistance, leukocyte >10,000/μl, CRP (≥20 and ≥ 2 mg/dl), detection of sigmoid diverticulitis using contrast medium. CT evidence. Conservative Tx possible.
  • Comments Comments (
    0
    ) |
Exclusion criteria Study Tx or other betalactam. Hypersensitivity to betalactam. Immunosuppressant use. Antibiotic Tx within 2 weeks before enrollment. Incurable hematological/oncological diseases. Pregnancy. Existing sigmoid diverticulitis requiring surgery.
  • Comments Comments (
    0
    ) |
if not an RCT, what was the directionality? Prospective
  • Comments Comments (
    0
    ) |
Specific population? No (all comers)
  • Comments Comments (
    0
    ) |
Was diverticulitis diagnosed with CT? CT
  • Comments Comments (
    0
    ) |
If NRCS, what analytic method was used to account for differences between study arms?
  • Comments Comments (
    0
    ) |


Baseline Characteristics
Question Antibiotic: Ertapenem Antibiotic: Ertapenem Total Comments
AnswerFollow-up AnswerFollow-up AnswerFollow-up
Participant race/ethnicity characteristics Male 54 Male 55.4 Male 54.7
  • Comments Comments (
    0
    ) |
Participant Age - Continuous data (in years) Mean 60.6 Mean 58.5 Mean 59.4
  • Comments Comments (
    0
    ) |
SD 12.2 SD 11.9 SD 12.1
  • Comments Comments (
    0
    ) |
Participant Age - Categorical data No data entered.
Participants with Un/Complicated Diverticulitis No data entered.
Specific Complications of Diverticulitis No data entered.
Number of Prior Episodes of Diverticulitis (categorical) No data entered.
History of (Prior) Complicated Diverticulitis No data entered.
KQ 4: Time Since Last Episode of Diverticulitis No data entered.
Note/Comment about baseline characteristics No data entered.
Number of Prior Episodes of Diverticulitis (continuous) No data entered.



Results & Comparisons


Results Data
Outcome: Adverse event - any      Population: All Participants
Time Point Measure Antibiotic: Ertapenem Antibiotic: Ertapenem


Baseline N/A

 N Analyzed 50 56
Counts 3 0
Percentage 5.1 0
Outcome: AE - Allergic reaction (major)      Population: All Participants
Time Point Measure Antibiotic: Ertapenem Antibiotic: Ertapenem


Baseline N/A

 N Analyzed 50 56
Counts 1 0
Percentage 2 0
Outcome: Adverse event - headache      Population: All Participants
Time Point Measure Antibiotic: Ertapenem Antibiotic: Ertapenem


Baseline N/A

 N Analyzed 50 56
Counts 2 0
Percentage 4 0
Outcome: AE - Serious (SAE)      Population: All Participants
Time Point Measure Antibiotic: Ertapenem Antibiotic: Ertapenem


Baseline N/A

 N Analyzed 50 56
Counts 0 0
Percentage 0 0
P-Value
Outcome: Treatment success rate      Population: All Participants Between-Arm Comparisons
Time Point Measure Antibiotic: Ertapenem Antibiotic: Ertapenem Comparison Measure Antibiotic: Ertapenem vs. Antibiotic: Ertapenem


1 months

 N Analyzed 50 56 N.S.
Counts 47 54
Percentage 94 96.4
P-Value
Outcome: Additional antibiotic therapy      Population: All Participants Between-Arm Comparisons
Time Point Measure Antibiotic: Ertapenem Antibiotic: Ertapenem Comparison Measure Antibiotic: Ertapenem vs. Antibiotic: Ertapenem


1 years

 N Analyzed 39 49 N.S.
Counts 4 3
Percentage 10.3 6.1
P-Value
Outcome: Recurrence      Population: All Participants Between-Arm Comparisons
Time Point Measure Antibiotic: Ertapenem Antibiotic: Ertapenem Comparison Measure Antibiotic: Ertapenem vs. Antibiotic: Ertapenem


1 years

 N Analyzed 40 48 N.S.
Counts 3 5
Percentage 7.5 10.4
P-Value
Outcome: Diverticulitis-related morbidities      Population: All Participants Between-Arm Comparisons
Time Point Measure Antibiotic: Ertapenem Antibiotic: Ertapenem Comparison Measure Antibiotic: Ertapenem vs. Antibiotic: Ertapenem


1 years

 N Analyzed 40 48 N.S.
Counts 1 1
Percentage 2.5 2.1
P-Value
Outcome: Parenteral nutrition      Population: All Participants Between-Arm Comparisons
Time Point Measure Antibiotic: Ertapenem Antibiotic: Ertapenem Comparison Measure Antibiotic: Ertapenem vs. Antibiotic: Ertapenem


5 days

 N Analyzed 50 56 <0.001
Counts 3 47
Percentage 6 83.9
P-Value
Outcome: Diverticulitis-related morbidities      Population: All Participants Between-Arm Comparisons
Time Point Measure Antibiotic: Ertapenem Antibiotic: Ertapenem Comparison Measure Antibiotic: Ertapenem vs. Antibiotic: Ertapenem


1 years

 N Analyzed 43 48 N.S.
Counts 1 0
Percentage 2.3 0
P-Value
Outcome: Abscess      Population: All Participants Between-Arm Comparisons
Time Point Measure Antibiotic: Ertapenem Antibiotic: Ertapenem Comparison Measure Antibiotic: Ertapenem vs. Antibiotic: Ertapenem


1 years

 N Analyzed 43 48 N.S.
Counts 1 0
Percentage 2.3 0
P-Value
Outcome: Surgery performed      Population: All Participants Between-Arm Comparisons
Time Point Measure Antibiotic: Ertapenem Antibiotic: Ertapenem Comparison Measure Antibiotic: Ertapenem vs. Antibiotic: Ertapenem


1 years

 N Analyzed 43 48 N.S.
Counts 16 21
Percentage 37.2 42.9
P-Value
Outcome: Length of hospital (or intensive care unit) stay      Population: All Participants Between-Arm Comparisons
Time Point Measure Antibiotic: Ertapenem Antibiotic: Ertapenem Comparison Measure Antibiotic: Ertapenem vs. Antibiotic: Ertapenem


Baseline days

 N Analyzed 50 56 0.002
Mean 7.8 9.7
SD 2.8 3.2
SE


Quality Dimensions
Dimension Value Notes Comments
Q14: Cochrane - Random sequence generation (selection bias): Selection bias (biased allocation to interventions) due to inadequate generation of a randomized sequence Unclear Information regarding random sequence is not provided.
  • Comments Comments (
    0
    ) |
Q15: Cochrane - Allocation concealment (selection bias): Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment Unclear Information regarding allocation concealment is not provided.
  • Comments Comments (
    0
    ) |
Q16: Cochrane - Blinding of participants (performance bias): Performance bias due to knowledge of the allocated interventions by participants during the study High Open-label
  • Comments Comments (
    0
    ) |
Q17: Cochrane - Blinding of personnel/ care providers (performance bias): Performance bias due to knowledge of the allocated interventions by personnel/care providers during the study. High Open-label
  • Comments Comments (
    0
    ) |
Q18: Cochrane - FOR OBJECTIVE OUTCOMES - Blinding of outcome assessor (detection bias): Detection bias due to knowledge of the allocated interventions by outcome assessors. No Open-label
  • Comments Comments (
    0
    ) |
Q20: Cochrane - Incomplete outcome data (attrition bias): Attrition bias due to amount, nature or handling of incomplete outcome data Low Reasons for missing outcome data was provided in Table 3. The percentage of drop-outs and withdrawals do not exceed 20%.
  • Comments Comments (
    0
    ) |
Q21: Cochrane - Selective Reporting (reporting bias): Reporting bias due to selective outcome reporting Unclear Study protocol is unavailable, but expected outcomes were reported.
  • Comments Comments (
    0
    ) |
Q22: Cochrane - Other Bias: Bias due to problems not covered elsewhere in the table. If yes, describe them in the Notes. Low Study appears to be free of other sources of bias.
  • Comments Comments (
    0
    ) |
Q1: ROBINS-I 1.1 Is there potential for confounding of the effect of intervention in this study?
  • Comments Comments (
    0
    ) |
Q3: ROBINS-I 1.4. Did the authors use an appropriate analysis method that controlled for all the important confounding domains?
  • Comments Comments (
    0
    ) |
Q4: ROBINS-I 1.5. If Y/PY to 1.4: Were confounding domains that were controlled for measured validly and reliably by the variables available in this study?
  • Comments Comments (
    0
    ) |
Q5: ROBINS-I 1.6. Did the authors control for any post-intervention variables that could have been affected by the intervention?
  • Comments Comments (
    0
    ) |
Q6: ROBINS-I - Risk of bias judgement for BIAS DUE TO CONFOUNDING
  • Comments Comments (
    0
    ) |
Q7: ROBINS-I 2.1. Was selection of participants into the study (or into the analysis) based on participant characteristics observed after the start of intervention?
  • Comments Comments (
    0
    ) |
Q8: ROBINS-I 2.2. If Y/PY to 2.1: Were the post-intervention variables that influenced selection likely to be associated with intervention?
  • Comments Comments (
    0
    ) |
Q9: ROBINS-I 2.3 If Y/PY to 2.2: Were the post-intervention variables that influenced selection likely to be influenced by the outcome or a cause of the outcome?
  • Comments Comments (
    0
    ) |
Q10: ROBINS-I 2.4. Do start of follow-up and start of intervention coincide for most participants?
  • Comments Comments (
    0
    ) |
Q12: ROBINS-I 2.5. If Y/PY to 2.2 and 2.3, or N/PN to 2.4: Were adjustment techniques used that are likely to correct for the presence of selection biases?
  • Comments Comments (
    0
    ) |
Q13: ROBINS-I - Risk of bias judgement for BIAS IN SELECTION OF PARTICIPANTS INTO THE STUDY
  • Comments Comments (
    0
    ) |
Q2: Did the study divide the follow up time of each individual participant into the different interventions?
  • Comments Comments (
    0
    ) |
Q11: Did the start and follow up calendar years coincide for most participants in the study?
  • Comments Comments (
    0
    ) |
Q19: Cochrane - FOR SUBJECTIVE OUTCOMES - Blinding of outcome assessor (detection bias): Detection bias due to knowledge of the allocated interventions by outcome assessors. No Open-label
  • Comments Comments (
    0
    ) |
Q23: NHLBI - Were eligibility/selection criteria for the study population prespecified and clearly described?
  • Comments Comments (
    0
    ) |
Q24: NHLBI - Was the test/service/intervention clearly described and delivered consistently across the study population?
  • Comments Comments (
    0
    ) |
Q25: NHLBI - Were the outcome measures prespecified, clearly defined, valid, reliable, and assessed consistently across all study participants?
  • Comments Comments (
    0
    ) |

Quality Rating
No quality rating data was found.